

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED

中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

“IGURATIMOD” API OBTAINED REGISTRATION CERTIFICATE FROM PMDA

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the active pharmaceutical ingredient (“**API**”) of “Iguratimod” produced by the Group has been granted an API registration certificate by the Pharmaceuticals and Medical Devices Agency (“**PMDA**”) of Japan and was approved for local marketing and sale. The approval of the API for sale in Japan signifies the Group’s continued advancement into the international high-end market.

Iguratimod is a new disease-modifying anti-rheumatic drug (DMARD) with anti-inflammatory, immunoglobulin-inhibiting, inflammatory factor-inhibiting, anti-bone resorption and bone-promoting effects. Compared to other traditional anti-rheumatic drugs, it not only inhibits the expression of relevant inflammatory factors and osteoclast activity, but also stimulates the expression of the transcription factor Osterix directly to facilitate osteoblast differentiation and promote bone reconstruction and bone health.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 11 March 2022

As at the date of this announcement, the Board of the Company comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.